Physician profile
Meredith Kehrer
NPI 1811992969
$5,315.09
in general payments reported to CMS, 2019-2025
38 companies · $1,447 in 2025
The $1,447 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $536 · 2020: $272 · 2022: $70.86 · 2023: $1,182 · 2024: $1,807 · 2025: $1,447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,436.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $824.50 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $585.30 | 2022-2025 | |
| Lilly USA, LLC | $553.37 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $459.35 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $424.65 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $407.51 | 2019-2025 | |
| Vanda Pharmaceuticals INC. | $256.82 | 2024-2025 | Hetlioz, Fanapt |
| Axsome Therapeutics, INC. | $194.65 | 2024-2025 | Auvelity |
| Amgen INC. | $187.47 | 2019-2025 | Repatha, Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.46 | 2019-2024 | Jardiance, Tradjenta, Synjardy |
| Otsuka America Pharmaceutical, INC. | $170.11 | 2023-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $123.89 | 2020-2025 | Spravato |
| Dynavax Technologies Corporation | $100.73 | 2024-2025 | Heplisav-B |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $86.78 | 2024-2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $78.80 | 2024-2025 | Voquezna |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $75.34 | 2019-2025 | Trintellix |
| Merck Sharp & Dohme LLC | $53.09 | 2023-2024 | Capvaxive, Gardasil 9, Gardasil |
| Idorsia Pharmaceuticals US INC | $52.17 | 2023-2024 | Quviviq |
| Exact Sciences Corporation | $46.50 | 2023-2025 | Cologuard Collection Kit |
| Medtronic, INC. | $43.78 | 2025 | Minimed 780g |
| Astellas Pharma US INC | $40.75 | 2019-2024 | Myrbetriq, Veozah |
| Alkermes, INC. | $40.72 | 2023-2025 | Lybalvi, Vivitrol |
| Allergan, INC. | $35.15 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.38 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.69 | 2019-2023 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $28.50 | 2019 | |
| Eisai INC. | $25.10 | 2019 | |
| Inspire Medical Systems, INC. | $19.47 | 2023 | Inspire |
| Boston Scientific Corporation | $18.96 | 2024 | |
| Lundbeck LLC | $17.71 | 2025 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $16.22 | 2025 | Zoryve |
| Amarin Pharma, INC. | $16.16 | 2019 | |
| Abbott Laboratories | $16.13 | 2023 | Freestyle Libre |
| Currax Pharmaceuticals LLC | $14.47 | 2025 | Contrave |
| E.R. Squibb & Sons, L.L.C. | $13.63 | 2019 | |
| Sanofi-Aventis U.S. LLC | $13.45 | 2023 | |
| Dexcom, INC. | $13.16 | 2023 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $12.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Kehrer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.